3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Cardiotoxicity
2
Breast Neoplasms
2
Renal Insufficiency, Chronic
1
Kidney Neoplasms
1
Heart Failure
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
69
Nivolumab
69
cabozantinib
45
Ipilimumab
38
Specimen Handling
33
Magnetic Resonance Spectroscopy
33
lenvatinib
26
Axitinib
25
belzutifan
21
Sunitinib
18
Biopsy
15
Radiosurgery
14
CTLA-4 Antigen
13
atezolizumab
12
Everolimus
10
pazopanib
8
fludarabine
8
avelumab
8
Bevacizumab
8
toripalimab
7
cemiplimab
7
Nephrectomy
7
Immunoglobulin G
7
Cyclophosphamide
7
aldesleukin
6
Standard of Care
6
Radiotherapy
6
Blood Specimen Collection
6
spartalizumab
5
palbociclib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
empagliflozin
×
1 year
×
Clear all
NCT06818305
2025-12-11
EmFin-Nx
Jinling Hospital, China
Phase 2
Terminated
10 enrolled